阿尔茨海默病中的生物标志物
Kayalvizhi Rajendran1, Uma Maheswari Krishnan2
1Centre for Nanotechnology & Advanced Biomaterials, SASTRA Deemed University, Thanjavur, India; School of Chemical & Biotechnology, SASTRA Deemed University, Thanjavur, India.
概括
这篇评论探讨了用于早期阿尔茨海默病 (AD) 诊断的生物流体中的蛋白质学. 在汗水,唾液和尿液中发现新的生物标志物,为在症状出现之前改善检测提供了希望.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 生物标志物发现发现
背景情况:
- 阿尔茨海默病 (AD) 是一种主要的神经退行性疾病,其特征是粉样质斑块和神经纤维状结.
- 目前的AD诊断方法 (例如成像) 往往缺乏准确性,无法及早发现疾病,从而限制了治疗的有效性.
- 现有的生物标志物 (例如,CSF粉样蛋白-β,tau) 主要跟踪疾病的进展,而不是早期诊断.
研究的目的:
- 审查蛋白质组学在识别新生物标志物的潜力,以早期和准确的阿尔茨海默病诊断.
- 探索各种生物流体 (汗水,血清,唾液,眼,尿液) 作为AD生物标志物发现的可访问来源.
- 突出使用生物流体的蛋白质组分析用于AD检测的挑战和进步.
主要方法:
- 对蛋白质组学研究的综合文献综述,分析生物流体对阿尔茨海默病生物标志物的分析.
- 对与早期AD相关的已识别的蛋白质生物标志物的分析.
- 评估各种生物流体来源的诊断潜力和局限性.
主要成果:
- 对生物流体的蛋白质组分析已经确定了阿尔茨海默病的几种候选生物标志物.
- 像汗水,唾液和尿液这样的替代生物流体显示出作为AD生物标志物的不那么侵入性来源的希望.
- 已识别的生物标志物需要进一步验证,以便在早期AD检测中临床应用.
结论:
- 蛋白质组学为发现可访问的生物标志物用于早期阿尔茨海默病诊断提供了一个有希望的途径.
- 除了脑脊液之外,研究生物流体对于开发非侵入性和准确的诊断工具至关重要.
- 需要进一步的研究和验证,以将这些蛋白质组发现转化为临床实践,以改善AD患者的治疗结果.
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110


